<DOC>
	<DOC>NCT00419926</DOC>
	<brief_summary>The purpose of this study is to determine if an initial intensified enteric-coated mycophenolate sodium (Myfortic) dosing regimen administered during the first six weeks post renal transplantation provides improved efficacy, with a similar safety profile, compared to a standard regimen of Myfortic.</brief_summary>
	<brief_title>Evaluation of the Therapeutic Benefit of an Initial Intensified Dosing Regimen of Mycophenolate Sodium Versus a Standard Regimen in Renal Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Males or females, 18 to 65 years old First or second time kidney transplant patients For females capable of becoming pregnant, negative pregnancy test prior to entry into trial and effective birth control during trial and 3 months after stopping trial medication Previous graft loss due to immunological reasons in the 1st year after the 1st transplant Multiorgan recipients or previous transplant of another organ, different from the kidney Recipients from a nonheartbeating donor Known hypersensitivity to mycophenolic acid or cyclosporine HIV positive or Hepatitis B surface antigen positive History of malignancy (past 5 years) Pregnancy or planned pregnancy, lactating, or unwillingness to use effective contraception. Evidence of severe liver disease Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Renal, Kidney, Intensified, Enteric-coated mycophenolate sodium, Transplant</keyword>
</DOC>